Company: BGLC
Filing Date: 2025-11-07
Form Type: S-3
Source: 0001477932-25-007976
Chunk: 41

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-07
Form: S-3
Chunk 41
---
 of such net proceeds will depend upon our funding requirements and the availability and cost of other funds. Our board of directors and management will have considerable discretion in the application of the net proceeds from this offering, and it is possible that we may allocate the proceeds differently than investors in the offering may desire or that we may fail to maximize the return on these proceeds. You will be relying on the judgment of our management with regard to the use of proceeds from this offering, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.

<div align='center'>DIVIDEND POLICY</div>

We have never declared or paid dividends on our common stock. We do not anticipate paying any dividends on our common stock in the foreseeable future. We currently intend to retain all available funds and any future earnings to fund the development and growth of our business. Any future determination to declare dividends will be subject to the discretion of our Board of Directors and will depend on various factors, including applicable laws, our results of operations, financial condition, future prospects and any other factors deemed relevant by our Board of Directors.

<div align='center'>DESCRIPTION OF SECURITIES WE ARE OFFERING</div>

Common Stock

We are offering up to $3,557,000 shares of our common stock in this offering pursuant to this prospectus supplement and the accompanying prospectus. As of November 5, 2025, there were 1,796,597 of common stock issued and outstanding, held by approximately 294 stockholders of record. Not reflected in the number of stockholders of record are persons who beneficially own shares of common stock held in nominee or street name. See “Descriptions of Capital Stock” beginning on page 7 in the accompanying prospectus for more information regarding our shares of common stock.

| S-13 |

<div align='center'>DILUTION</div>

Our net tangible book value on June 30, 2025 was approximately $7,522,037, or $4.19 per share. “Net tangible book value” is total assets minus the sum of liabilities and intangible assets. “Net tangible book value per share” is net tangible book value divided by the total number of shares of our outstanding common stock.

After giving effect to the sale of 659,925 shares of common stock in this offering, at an assumed offering price of $5.39 per share, which was the last reported sale price of our common stock on the Nasdaq Capital Market on November